镰状细胞贫血治疗市场规模、份额、成长分析、按治疗、按最终用途、按地区 - 行业预测，2024-2031 年

镰状贫血治疗的全球市场规模预计将在2022 年达到21 亿美元，从2023 年的25.5 亿美元增长到2031 年的120.3 亿美元，预计在预测期内（2024-2031 年）将以复合年成长率成长。

全球镰状细胞病患疾病的上升预计将极大地推动对有效治疗的需求，特别是在遗传倾向和意识较低的地区，例如非洲、中东和印度。增加对新治疗方法研究的投资为该领域的公司提供了机会。此外，政府和非营利组织旨在提高意识的支持努力也可能扩大市场前景。从长远来看，创新药物的涌入和不断扩大的治疗管道可能会推动市场成长。然而，新治疗方法的安全性问题、基因疗法复杂的法规环境以及持续缺乏认知等挑战可能会阻碍 2031 年后全球镰状细胞疾病治疗市场的进展。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 抑制因素和挑战
• 波特分析与影响
  • 竞争公司之间的敌对关係
  • 替代品的威胁
  • 买方议价能力
  • 新进入者的威胁
  • 供应商的议价能力

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2023）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 技术进步
• 监管环境
• 案例研究

镰状细胞性贫血治疗市场规模：依治疗分类

• 市场概况
• 骨髓移植
• 输血
• 药物治疗
  • 羟基脲
  • 品牌产品

以最终用途分類的镰状细胞贫血治疗市场规模

• 市场概况
• 医院
• 专科诊所
• 其他的

按地区分類的镰状细胞贫血治疗市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 英国
  • 德国
  • 西班牙
  • 法国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2023）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2021-2023）

主要企业简介

• Novartis AG
• Emmaus Medical, Inc.
• Addmedica
• Medunik USA
• Global Blood Therapeutics, Inc.
• Bristol Myers Squibb Co.
• Sanofi SA
• Bluebird Bio
• Pfizer Inc.
• Aruvant Sciences, Inc.
• Glycomimetics, Inc.
• Editas Medicine, Inc.
• CRISPR Therapeutics
• F. Hoffmann-La Roche Ltd
• Janssen Pharmaceuticals
• Merck & Co., Inc.
• AstraZeneca
• Gilead Sciences
• Vertex Pharmaceuticals
• Hemanext

结论和建议

Global Sickle Cell Disease Treatment Market size was valued at USD 2.10 billion in 2022 and is poised to grow from USD 2.55 billion in 2023 to USD 12.03 billion by 2031, growing at a CAGR of 4.1 % in the forecast period (2024-2031).

The rising global incidence of sickle cell disease is expected to significantly drive demand for effective treatments, particularly in regions like Africa, the Middle East, and India, where genetic predisposition and limited awareness prevail. Greater investment in research for novel therapies presents opportunities for companies in this sector. Additionally, supportive initiatives from governments and non-profits aimed at increasing awareness will broaden market prospects. The influx of innovative drugs and expanded treatment pipelines is set to enhance market growth in the long term. However, challenges such as safety concerns with new treatments, a complex regulatory environment for genetic therapies, and ongoing awareness deficits may hinder progress in the global sickle cell disease treatment market through 2031 and beyond.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Sickle Cell Disease Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Sickle Cell Disease Treatment Market Segmental Analysis

Global Sickle Cell Disease Treatment Market is segmented by Treatment, End-use and region. Based on Treatment, the market is segmented into Blood Transfusion, Bone Marrow Transplant, Pharmacotherapy (Hydroxyurea, Branded Products). Based on End-use, the market is segmented into Hospitals, Specialty Clinics, Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Sickle Cell Disease Treatment Market

The increasing prevalence of sickle cell disease is a significant driver for the global treatment market. Factors such as genetic factors and inadequate early detection have contributed to a sharp rise in cases worldwide. Regions such as Africa, India, and the Middle East are projected to have particularly high rates of sickle cell disease, presenting lucrative opportunities for treatment providers in these areas. As awareness and the need for effective treatment options grow, these markets are becoming increasingly attractive for healthcare companies focused on addressing the challenges posed by this condition and improving patient outcomes.

Restraints in the Global Sickle Cell Disease Treatment Market

A significant restraint in the Global Sickle Cell Disease Treatment market is the limited awareness and diagnosis among the public. Many individuals remain unaware of the symptoms associated with sickle cell disease, leading to delays in seeking medical attention and subsequent diagnosis. Furthermore, the inadequate diagnostic infrastructure in various regions exacerbates this issue, resulting in numerous cases either going undetected or being diagnosed too late for effective treatment. This combination of lack of awareness and insufficient diagnostic capabilities hinders the overall demand for sickle cell disease therapies, posing a challenge for growth in the treatment market moving forward.

Market Trends of the Global Sickle Cell Disease Treatment Market

The Global Sickle Cell Disease Treatment market is witnessing a burgeoning trend centered around collaborative efforts aimed at enhancing treatment accessibility. Varying availability of therapies across regions has hindered the adoption of innovative treatments, prompting partnerships among governments, non-profit organizations, and healthcare companies. These collaborations seek to improve the affordability and accessibility of therapies, thereby promoting patient access and increasing market penetration. As stakeholders unite to address the disparities in treatment availability, the market is poised for significant growth, leading to improved patient outcomes and revenue generation in the long run, while fostering a more equitable healthcare landscape for sickle cell disease management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Regulatory Landscape
• Case Studies

Global Sickle Cell Disease Treatment Market Size by Treatment & CAGR (2024-2031)

• Market Overview
• Bone Marrow Transplant
• Blood Transfusion
• Pharmacotherapy
  • Hydroxyurea
  • Branded Products

Global Sickle Cell Disease Treatment Market Size by End-use & CAGR (2024-2031)

• Market Overview
• Hospitals
• Specialty Clinics
• Others

Global Sickle Cell Disease Treatment Market Size & CAGR (2024-2031)

• North America, (Treatment, End-use)
  • US
  • Canada
• Europe, (Treatment, End-use)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific, (Treatment, End-use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America, (Treatment, End-use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa, (Treatment, End-use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emmaus Medical, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Addmedica
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medunik USA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Global Blood Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bluebird Bio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aruvant Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glycomimetics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Editas Medicine, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CRISPR Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hemanext
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation